GKOS

Glaukos Corporation (GKOS) shares have gained 36.8% over six months, outperforming its industry, driven by strong Q2 results with 50% revenue growth to $185.6 million, successful commercial expansion of Epioxa for keratoconus treatment, positive clinical data for iDose TR, and pipeline advances including a new retinal disease licensing agreement. The company raised its 2026 revenue guidance to $680-$700 million.

Glaukos Corporation announced a licensing agreement with RevOpsis Therapeutics to develop RO-104, a first-in-class tri-specific biologic for retinal diseases, and gained exclusive access to the RevMod platform for up to four additional retinal biologic candidates. Despite the strategic expansion, GKOS stock declined 6.3% following the announcement, though it has gained 42.8% year-to-date.

Inspire Medical Systems (INSP) shares gained 47.8% over three months as reimbursement uncertainty eases following new CPT code approvals and better-than-expected Q2 results. The company reported $200.6M in revenues and 14 cents adjusted EPS, while Project Horizon aims to redirect $30M in annualized savings toward growth initiatives. However, near-term sales remain disrupted and full execution risks persist.

DaVita (DVA) shares have gained 55.6% year-to-date, outpacing industry growth, driven by better operating execution, improved treatment-volume outlook, and growing confidence in value-based kidney care. The company reaffirmed 2026 guidance with expected earnings growth of 50.6% on 3.2% sales growth, supported by higher revenue per treatment and labor productivity gains. However, risks include insurance-mix headwinds from ACA subsidy losses, rising patient-care costs, and uncertain Medicare reimbursement policies.

Becton, Dickinson and Company (BDX) has gained 25.5% over six months, driven by successful portfolio realignment following its Life Sciences separation, strong earnings growth across high-growth platforms, and a major $19 billion U.S. manufacturing partnership agreement. The company raised its fiscal 2026 EPS guidance and returned $3.1 billion to shareholders, though it faces headwinds from tariffs, Alaris remediation, and China vaccine weakness.

Forge's Fierce Life Sciences announced finalists for the 2026 Fierce Life Science and Healthcare Innovation Awards, recognizing breakthrough innovations across AI, biotechnology, digital health, and medical devices. The inaugural Fierce Vanguard Gala on November 19, 2026, in New York City will consolidate three recognition programs (Fierce 50, Fierce 15, and Innovation Awards) and announce winners live.

Intuitive Surgical's single-port (SP) platform is emerging as a significant growth franchise with 61% year-over-year procedure growth and an installed base of 445 systems. Strong U.S. utilization gains (25% YoY) and expanding stapler adoption (nearly 60% of eligible cases) support the platform's trajectory toward becoming a billion-dollar business. The company is also expanding internationally and through product innovation.